Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Lanning Newell

Gastroenterology Raleigh, NC Medical Doctor

NPI 1114926250 CMS profile 5385

2600 Atlantic Ave, Raleigh, NC 27604

Open in the dashboard

General payments

$6,364

325 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Lanning Newell of Raleigh, NC is reported in the CMS Open Payments database as having received $6,364 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $963 43
2022 General $1,591 82
2021 General $1,598 83
2020 General $823 48
2019 General $1,389 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lanning Newell
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Lanning Newell were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Lanning Newell Gastroenterology median Middle half National median
2019 $1,389 $417 $126–$1,100 $163
2020 $823 $224 $74–$624 $114
2021 $1,598 $352 $106–$1,054 $132
2022 $1,591 $448 $129–$1,270 $149
2023 $963 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $1,938 98 payments
  2. Gilead Sciences, Inc. $896 53 payments
  3. Pfizer Inc. $668 34 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $416 23 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $402 23 payments
  6. Intercept Pharmaceuticals, Inc. $310 9 payments
  7. RedHill Biopharma Inc. $265 9 payments
  8. Celgene Corporation $240 13 payments
  9. Janssen Biotech, Inc. $233 10 payments
  10. Ferring Pharmaceuticals Inc. $179 11 payments
  11. Other $817 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,176 318 payments
  2. Education $116 3 payments
  3. Gift $72 4 payments
Products named General payments · program years 2019–2023
  1. XELJANZ $616 30 payments
  2. HUMIRA $531 27 payments
  3. SKYRIZI $519 19 payments
  4. STELARA $405 14 payments
  5. RINVOQ $350 13 payments
  6. ENTYVIO $295 14 payments
  7. ZEPOSIA $267 15 payments
  8. Talicia $265 9 payments
  9. XIFAXAN $247 14 payments
  10. INFLECTRA $242 16 payments
  11. Other $2,388 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

19

Median for Specialist: 51

Drug cost

$92

Median for Specialist: $1,236

Branded share of claims

0%

Median for Specialist: 21.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 19 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record